Blacksburg biotech company Landos Biopharma Inc. has gone public.
An initial public offering of stock, priced at $16 a share, was expected to raise $100 million to develop possible new treatments for autoimmune diseases.
The Landos labs at the Virginia Tech Corporate Research Center have “identified seven novel immunometabolic targets and product candidates” for the treatment of such ailments as ulcerative colitis, Crohn’s disease, lupus, rheumatoid arthritis, multiple sclerosis, Alzheimer’s disease, asthma, psoriasis, chronic obstructive pulmonary disease and type 1 diabetes.
Those descriptions and scores of scientific charts have been filed by Landos with the U.S. Securities and Exchange Commission.
Click here to read more via The Roanoke Times.
Latest posts by BioBuzz Media (see all)
- Altimmune Commences Enrollment In Phase 1 Clinical Trial Of AdCOVID™ — A Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate - February 25, 2021
- New Chief Investment Officer to Lead TEDCO’s Investment Activities - February 24, 2021
- BioFactura Funded $13 Million Contract Option for its Smallpox Biodefense Therapeutic - February 23, 2021